{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:42:46Z","timestamp":1787002966431,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (\n                    <jats:italic>RUNX1<\/jats:italic>\n                    + AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the prognostic value of\n                    <jats:italic>RUNX1<\/jats:italic>\n                    mutation after allogeneic stem cell transplantation (alloSCT). All consecutive adults undergoing alloSCT for AML in first complete remission (CR1) between 2013 and 2019 with complete information on conventional cytogenetics and\n                    <jats:italic>RUNX1<\/jats:italic>\n                    mutational status were included. Endpoints of interest were cumulative relapse incidence, non-relapse mortality, overall and leukemia-free survival (OS\/LFS), and GvHD-free\/relapse-free survival. A total of 674 patients (183\n                    <jats:italic>RUNX1<\/jats:italic>\n                    +, 491\n                    <jats:italic>RUNX1<\/jats:italic>\n                    \u2212) were identified, with &gt;85% presenting as\n                    <jats:italic>de novo<\/jats:italic>\n                    AML. Median follow-up was 16.4 (\n                    <jats:italic>RUNX1<\/jats:italic>\n                    +) and 21.9 (\n                    <jats:italic>RUNX1<\/jats:italic>\n                    \u2212) months. Survival rates showed no difference between\n                    <jats:italic>RUNX1<\/jats:italic>\n                    + and\n                    <jats:italic>RUNX1<\/jats:italic>\n                    \u2212 patients either in univariate or multivariate analysis (2-year OS: 67.7 vs. 66.1%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.7; 2-year LFS: 61.1 vs. 60.8%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.62). Multivariate analysis identified age, donor type and poor cytogenetics as risk factors for inferior outcome. Among patients with\n                    <jats:italic>RUNX+<\/jats:italic>\n                    AML, older age, reduced intensity conditioning and minimal residual disease at alloSCT predicted inferior outcome. Our data provide evidence that the negative influence of\n                    <jats:italic>RUNX1<\/jats:italic>\n                    mutations in patients with AML can be overcome by transplantation in CR1.\n                  <\/jats:p>","DOI":"10.1038\/s41409-021-01322-w","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T05:24:00Z","timestamp":1622784240000},"page":"2445-2453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-1590","authenticated-orcid":false,"given":"Johanna","family":"Waidhauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-4748","authenticated-orcid":false,"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-648X","authenticated-orcid":false,"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn","family":"Van Gorkom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas","family":"Schaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eefke","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Bunjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-487X","authenticated-orcid":false,"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Acute Leukemia Working Party of EBMT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"1322_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"1322_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","volume":"31","author":"J Prada-Arismendy","year":"2017","unstructured":"Prada-Arismendy J, Arroyave JC, Rothlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31:63\u201376. https:\/\/doi.org\/10.1016\/j.blre.2016.08.005","journal-title":"Blood Rev"},{"key":"1322_CR3","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1182\/blood-2009-05-223784","volume":"114","author":"JL Tang","year":"2009","unstructured":"Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, et al. AML1\/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114:5352\u201361. https:\/\/doi.org\/10.1182\/blood-2009-05-223784","journal-title":"Blood"},{"key":"1322_CR4","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/blood-2009-11-255976","volume":"117","author":"S Schnittger","year":"2011","unstructured":"Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117:2348\u201357. https:\/\/doi.org\/10.1182\/blood-2009-11-255976","journal-title":"Blood"},{"key":"1322_CR5","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/jco.2010.30.7926","volume":"29","author":"VI Gaidzik","year":"2011","unstructured":"Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Rock J, Paschka P, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol : Off J Am Soc Clin Oncol. 2011;29:1364\u201372. https:\/\/doi.org\/10.1200\/jco.2010.30.7926","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"1322_CR6","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/jco.2011.40.6652","volume":"30","author":"JH Mendler","year":"2012","unstructured":"Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol : Off J Am Soc Clin Oncol. 2012;30:3109\u201318. https:\/\/doi.org\/10.1200\/jco.2011.40.6652","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"1322_CR7","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/leu.2016.126","volume":"30","author":"VI Gaidzik","year":"2016","unstructured":"Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30:2160\u20138. https:\/\/doi.org\/10.1038\/leu.2016.126","journal-title":"Leukemia"},{"key":"1322_CR8","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3324\/haematol.2012.064667","volume":"97","author":"PA Greif","year":"2012","unstructured":"Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica. 2012;97:1909\u201315. https:\/\/doi.org\/10.3324\/haematol.2012.064667","journal-title":"Haematologica"},{"key":"1322_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"1322_CR10","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children\u2019s Leukaemia Working Parties. Blood. 1998;92:2322\u201333.","journal-title":"Blood"},{"key":"1322_CR11","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD Grading. Bone Marrow Transplant 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1322_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transpl"},{"key":"1322_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3324\/haematol.2016.144139","volume":"102","author":"SR McCurdy","year":"2017","unstructured":"McCurdy SR, Kasamon YL, Kanakry CG, Bola\u00f1os-Meade J, Tsai HL, Showel MM, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017;102:391\u2013400. https:\/\/doi.org\/10.3324\/haematol.2016.144139","journal-title":"Haematologica"},{"key":"1322_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3324\/haematol.2014.114157","volume":"100","author":"P Paschka","year":"2015","unstructured":"Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, et al. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica. 2015;100:324\u201330. https:\/\/doi.org\/10.3324\/haematol.2014.114157","journal-title":"Haematologica"},{"key":"1322_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1182\/blood-2017-12-819789","volume":"131","author":"RKY Sood","year":"2018","unstructured":"Sood RKY, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2018;131:373 https:\/\/doi.org\/10.1182\/blood-2017-12-819789","journal-title":"Blood"},{"key":"1322_CR16","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2015-06-651562","volume":"126","author":"C Schmid","year":"2015","unstructured":"Schmid C, Labopin M, Soci\u00e9 G, Daguindau E, Volin L, Huynh A, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 2015;126:2062\u20139. https:\/\/doi.org\/10.1182\/blood-2015-06-651562","journal-title":"Blood"},{"key":"1322_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-017-0393-3","volume":"10","author":"X Poir\u00e9","year":"2017","unstructured":"Poir\u00e9 X, Labopin M, Maertens J, Yakoub-Agha I, Blaise D, Ifrah N, et al. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol 2017;10:20 https:\/\/doi.org\/10.1186\/s13045-017-0393-3","journal-title":"J Hematol Oncol"},{"key":"1322_CR18","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1200\/jco.2016.67.3616","volume":"34","author":"MG Della Porta","year":"2016","unstructured":"Della Porta MG, Galli A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol : Off J Am Soc Clin Oncol. 2016;34:3627\u201337. https:\/\/doi.org\/10.1200\/jco.2016.67.3616","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"1322_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1080\/10428194.2018.1522439","volume":"60","author":"A Stengel","year":"2019","unstructured":"Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C. RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome. Leuk Lymphoma. 2019;60:1334\u20136. https:\/\/doi.org\/10.1080\/10428194.2018.1522439","journal-title":"Leuk Lymphoma"},{"key":"1322_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2991\/chi.d.200408.001","volume":"2","author":"J Shreve","year":"2020","unstructured":"Shreve J, Nazha A. The evolving landscape of myelodysplastic syndrome prognostication. Clin Hematol Int. 2020;2:43\u20138. https:\/\/doi.org\/10.2991\/chi.d.200408.001","journal-title":"Clin Hematol Int"},{"key":"1322_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241\u20137. https:\/\/doi.org\/10.1038\/leu.2013.336","journal-title":"Leukemia"},{"key":"1322_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-019-03606-0","volume":"98","author":"E Cheung","year":"2019","unstructured":"Cheung E, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, Benitez LL, et al. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann Hematol. 2019;98:541\u201359. https:\/\/doi.org\/10.1007\/s00277-019-03606-0","journal-title":"Ann Hematol"},{"key":"1322_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0296-3","volume":"10","author":"AK Schmaelter","year":"2020","unstructured":"Schmaelter AK, Labopin M, Soci\u00e9 G, It\u00e4l\u00e4-Remes M, Blaise D, Yakoub-Agha I, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10:26 https:\/\/doi.org\/10.1038\/s41408-020-0296-3","journal-title":"Blood Cancer J"},{"key":"1322_CR24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1200\/jco.2014.58.3518","volume":"33","author":"X Chen","year":"2015","unstructured":"Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33:1258\u201364. https:\/\/doi.org\/10.1200\/jco.2014.58.3518","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1322_CR25","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/jco.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:1190\u20137. https:\/\/doi.org\/10.1200\/jco.2010.31.8121","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1322_CR26","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"MH Gilleece","year":"2018","unstructured":"Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Soci\u00e9 G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93:1142\u201352. https:\/\/doi.org\/10.1002\/ajh.25211","journal-title":"Am J Hematol"},{"key":"1322_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01005-y","author":"A Nagler","year":"2020","unstructured":"Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transpl. 2020. https:\/\/doi.org\/10.1038\/s41409-020-01005-y","journal-title":"Bone Marrow Transpl"},{"key":"1322_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00277-014-2072-6","volume":"93","author":"M Port","year":"2014","unstructured":"Port M, B\u00f6ttcher M, Thol F, Ganser A, Schlenk R, Wasem J, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol. 2014;93:1279\u201386. https:\/\/doi.org\/10.1007\/s00277-014-2072-6","journal-title":"Ann Hematol"},{"key":"1322_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/leu.2017.239","volume":"32","author":"A Stengel","year":"2018","unstructured":"Stengel A, Kern W, Meggendorfer M, Nadarajah N, Perglerov\u00e0 K, Haferlach T, et al. Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML. Leukemia. 2018;32:295\u2013302. https:\/\/doi.org\/10.1038\/leu.2017.239","journal-title":"Leukemia"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01322-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01322-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01322-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T05:01:07Z","timestamp":1633064467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01322-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01322-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"assertion":[{"value":"23 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}